FDA approves Merck’s RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
But older children, who had no access to the shots, had higher rates this winter compared with last
New vaccines and treatments are linked to a dramatic decline in RSV hospitalizations for babies, acc…